10月9日，针对"圣湘董事长戴立忠创立核聚变公司"的消息，圣湘生物方面向中国证券报记者回应称， 戴立忠是鸿鹄聚变(上海)能源科技有限公司(简称"鸿鹄聚变")实控人，目前该项目只涉及戴立忠个人投 资，戴立忠不参与鸿鹄聚变的日常运营工作。 仅涉及个人投资 圣湘生物也在投资者互动平台上做了回应，聚变能源作为有望彻底解决全球能源危机和环境问题的终极 能源形式，已成为全球能源科技竞争的战略高地，上海市已明确将核聚变列为重点发展的未来产业。鸿 鹄聚变成立于2023年，系圣湘生物实控人、董事长戴立忠投资创立的企业，也是国内专注于高温超导仿 星器路线的商业聚变企业。 已关注和研究多年 圣湘生物是以自主创新基因技术为核心，集体外诊断试剂、仪器、第三方医学检验服务及生物制药为一 体的诊疗一体化方案提供商。公司2025年半年报显示，公司上半年共实现营收8.69亿元，同比增长 21.15%；实现归母净利润1.63亿元，同比增长3.84%；实现扣非净利润1.36亿元，同比增长12.19%。 圣湘生物2024年年报显示，戴立忠系北京大学学士，美国普林斯顿大学硕士、博士，麻省理工学院博士 后，现任圣湘生物法定代表人、董事长、总经理。先后当 ...

核聚变赛道有多大吸引力？ 据证券时报，针对"圣湘董事长戴立忠创立核聚变公司"的消息，圣湘生物方面向记者回应称，戴立忠是鸿鹄聚变（上海）能源科技有限公司投资人与实控 人，目前该项目只涉及戴立忠个人投资，戴立忠不参与鸿鹄聚变的的日常运营工作。 据公司官网介绍，圣湘生物科技股份有限公司是以自主创新基因技术为核心，集体外诊断试剂、仪器、第三方医学检验服务及生物制药为一体的诊疗一体 化方案提供商。公司在科创板上市（股票代码：，并跻身中国医药工业百强及全球医疗器械企业TOP100榜单。 公司以长沙、上海为双战略支点，辐射全国、布局全球。在北京、成都、广州、武汉等全国主要城市和英国、法国、美国、印尼、菲律宾、泰国等全球重 要区域设立了分子公司或分支机构，构建起全球化运营网络。 来源：wind 公开资料显示，戴立忠，1968年7月出生，中国国籍，无境外永久居留权。北京大学学士，美国普林斯顿大学硕士、博士，麻省理工学院博士后。先后当 选第十三届、十四届全国人大代表，第三届中国慈善联合会副会长；是国家高层次人才，国务院特殊津贴专家，中国侨界十杰，长沙市A类人才（国际顶 尖人才）；荣获国家科技进步二等奖、全国创新争先奖、中国专利银 ...

Company Overview - Mingde Biological Technology Co., Ltd. specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as information solutions for critical care and third-party medical testing services [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - As of the first quarter of 2025, the company reported a revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, showing a year-on-year decline of 111.43% [1] - The sales gross margin stood at 16.37% [1] Market Position - The company's current stock price is 21.53 yuan, with a PE ratio of 129.01, significantly higher than the industry average of 55.91 and the industry median of 40.36 [2] - Mingde Biological's total market capitalization is 5.006 billion yuan [1][2] - As of the first quarter of 2025, there are 2 institutional investors holding shares in the company, with a total holding of 123,100 shares valued at 0.02 million yuan [1]

8月15日，明德生物今日收盘20.77元，下跌1.05%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到124.46倍，总市值48.29亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.58倍，行业中值39.97倍，明德生物排 名第108位。 资金流向方面，8月15日，明德生物主力资金净流出1145.22万元，近5日总体呈流出状态，5日共流出 4145.34万元。 武汉明德生物科技股份有限公司的主营业务是体外诊断试剂和诊断仪器的研发、生产、销售和服务。公 司的主要产品是体外诊断试剂和仪器、急危重症信息化解决方案、第三方医学检验服务。 最新一期业绩显示，2025年一季报，公司实现营业收入6996.03万元，同比14.76%；净利润-3662988.06 元，同比-111.43%，销售毛利率16.37%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13明德生物124.4664.810.8348.29亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9157.03亿1九安医疗11.3611.490.89191.70亿2英科医疗 15.6 ...

Core Viewpoint - Mingde Biological's stock closed at 20.99 yuan, down 2.01%, with a rolling PE ratio of 125.77 times, indicating a significant premium compared to the industry average [1] Company Summary - Mingde Biological focuses on the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as solutions for critical care information and third-party medical testing services [1] - For Q1 2025, the company reported revenue of 69.96 million yuan, a year-on-year increase of 14.76%, but a net loss of approximately 3.66 million yuan, reflecting a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1] Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Mingde Biological at the 108th rank within the industry [1] - As of Q1 2025, there are 2 institutional investors holding shares in Mingde Biological, with a total holding of 123,100 shares valued at 0.02 million yuan [1]

Company Overview - Mingde Biological Technology Co., Ltd. specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - For Q1 2025, the company reported a revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, showing a year-on-year decline of 111.43% [1] - The gross profit margin for the company stood at 16.37% [1] Market Position - As of July 23, the company's stock closed at 22.03 yuan, with a PE ratio of 132.01, marking a new low in 318 days [1] - The total market capitalization of the company is 5.122 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 53.52, with a median of 37.14, placing Mingde Biological at the 108th position in the industry ranking [1][2] Shareholder Information - As of July 10, 2025, the number of shareholders for Mingde Biological is 24,757, a decrease of 81 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

Company Overview - Mingde Biological Technology Co., Ltd. specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as information solutions for critical care and third-party medical testing services [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - For Q1 2025, the company reported revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, showing a year-on-year decline of 111.43% [1] - The gross profit margin for the company stood at 16.37% [1] Market Position - As of July 11, the company's stock closed at 20.15 yuan, down 1.32%, with a rolling price-to-earnings (PE) ratio of 120.74 times [1] - The total market capitalization of the company is 4.685 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 52.06 times, with a median of 37.22 times, placing Mingde Biological at the 108th position in the industry [1][2] Shareholder Information - As of June 30, 2025, the number of shareholders for Mingde Biological is 24,838, a decrease of 200 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Mingde Biological Technology Co., Ltd., particularly its stock performance and valuation metrics [1][2] - As of July 3, the closing price of Mingde Biological was 20.7 yuan, reflecting a 2.48% increase, with a rolling PE ratio of 124.04, marking a new low in 17 days, and a total market capitalization of 4.813 billion yuan [1] - The average PE ratio for the medical device industry is 51.48, with a median of 36.88, positioning Mingde Biological at the 108th rank within the industry [1][2] Group 2 - As of the first quarter of 2025, six institutions held shares in Mingde Biological, including four funds and two insurance companies, with a total holding of 13.8456 million shares valued at 250 million yuan [1] - The main business of Mingde Biological includes the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as solutions for critical care information and third-party medical testing services [1] - The latest financial report for the first quarter of 2025 shows that the company achieved a revenue of 69.9603 million yuan, a year-on-year increase of 14.76%, while the net profit was -3.662988 million yuan, a year-on-year decrease of 111.43%, with a gross profit margin of 16.37% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Mingde Biological, which closed at 21.46 yuan, up 9.99%, with a rolling PE ratio of 128.59, marking a new low in 280 days, and a total market capitalization of 4.99 billion yuan [1][2] - The average PE ratio for the medical device industry is 50.97, with a median of 36.67, positioning Mingde Biological at the 109th rank within the industry [1][2] - As of the first quarter of 2025, six institutions hold shares in Mingde Biological, including four funds and two insurance companies, with a total holding of 13.84 million shares valued at 250 million yuan [1] Group 2 - Mingde Biological specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, with key products including in vitro diagnostic reagents, critical care information solutions, and third-party medical testing services [1] - The latest financial results for the first quarter of 2025 show that the company achieved a revenue of 69.96 million yuan, a year-on-year increase of 14.76%, while net profit was -3.66 million yuan, a year-on-year decrease of 111.43%, with a gross profit margin of 16.37% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Mingde Biological Technology Co., Ltd., particularly its stock performance and industry comparison [1][2] - As of June 3, the closing price of Mingde Biological was 19.71 yuan, with a PE ratio of 118.10, marking a new low in 111 days, and a total market capitalization of 4.583 billion yuan [1] - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, positioning Mingde Biological at the 108th rank within the industry [1][2] Group 2 - As of April 18, 2025, the number of shareholders for Mingde Biological was 25,248, a decrease of 345 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of the company includes the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as solutions for critical care information and third-party medical testing services [1] - In the latest quarterly report for Q1 2025, the company reported a revenue of 69.96 million yuan, a year-on-year increase of 14.76%, but a net loss of approximately 3.66 million yuan, representing a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1]